Home > > > > > Report Detail

Chronic Traumatic Encephalopathy - Pipeline Insight, 2021

Publisher Name :
Date: 10-Feb-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Chronic Traumatic Encephalopathy - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Chronic traumatic encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Chronic Traumatic Encephalopathy Understanding

Chronic Traumatic Encephalopathy: Overview

Chronic traumatic encephalopathy is characterized by progressive neurodegeneration of brain due to repetitive traumatic brain injuries, including concussions as well as repeated blow to the head. Athletes who play contact sports such as boxing, football, and military veterans are at greater risk for CTE owing to their increased chances of enduring frequent and repeated blows to the head.

"Chronic Traumatic Encephalopathy- Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Traumatic Encephalopathy pipeline landscape is provided which includes the disease overview and Chronic Traumatic Encephalopathy treatment guidelines. The assessment part of the report embraces, in depth Chronic Traumatic Encephalopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Traumatic Encephalopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Traumatic Encephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Traumatic Encephalopathy.

Chronic Traumatic Encephalopathy Emerging Drugs Chapters

This segment of the chronic traumatic encephalopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Traumatic Encephalopathy Emerging Drugs

- N-acetylcysteine Amide (NACA): Brighton Biotech, Inc.

Brighton Biotech's lead drug candidate, N-acetylcysteine Amide, is a small anti-oxidant molecule in development for the treatment of CTE. It is a potential drug to attenuate the destructive effects of oxidation while brain injuries.

Further product details are provided in the report……..

Chronic Traumatic Encephalopathy: Therapeutic Assessment

This segment of the report provides insights about the different chronic traumatic encephalopathy drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Chronic Traumatic Encephalopathy

There are approx. 3+ key companies which are developing the therapies for chronic traumatic encephalopathy. The companies which have their chronic traumatic encephalopathy drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Brighton Biotech, Inc. and others.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

- Mid-stage products (Phase II and Phase I/II)

- Early-stage products (Phase I/II and Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Chronic traumatic encephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Subcutaneous

- Intravenous

- Oral

- Intramuscular

- Molecule Type

Products have been categorized under various Molecule types such as

- Small molecules

- Natural metabolites

- Monoclonal antibodies

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Traumatic Encephalopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses chronic traumatic encephalopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging chronic traumatic encephalopathy drugs.

Chronic Traumatic Encephalopathy Report Insights

- Chronic Traumatic Encephalopathy Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Chronic Traumatic Encephalopathy Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing chronic traumatic encephalopathy drugs?

- How many chronic traumatic encephalopathy drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of chronic traumatic encephalopathy?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the chronic traumatic encephalopathy therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for chronic traumatic encephalopathy and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Brighton Biotech Inc.

- Tetra Therapeutics

Key Products

- N-acetylcysteine Amide (NACA)

- PDE4B inhibitor

Chronic Traumatic Encephalopathy - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Chronic Traumatic Encephalopathy: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Chronic Traumatic Encephalopathy - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• Chronic Traumatic Encephalopathy companies' collaborations, Licensing, Acquisition -Deal Value Trends
Chronic Traumatic Encephalopathy Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Pre-clinical and Discovery Stage Products
• Comparative Analysis
N-acetylcysteine Amide: Brighton Biotech Inc.
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Chronic Traumatic Encephalopathy Key Companies
Chronic Traumatic Encephalopathy Key Products
Chronic Traumatic Encephalopathy- Unmet Needs
Chronic Traumatic Encephalopathy- Market Drivers and Barriers
Chronic Traumatic Encephalopathy- Future Perspectives and Conclusion
Chronic Traumatic Encephalopathy Analyst Views
Chronic Traumatic Encephalopathy Key Companies
Appendix

List of Tables

Table 1 Total Products for Chronic Traumatic Encephalopathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Chronic Traumatic Encephalopathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global Restless Legs Syndrome Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 112
    According to our LPI (LP Information) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2023. With growing demand in downstream market, the Restless Legs Syndrome is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Restless Legs Syndrome market. Restless Legs Syndrome are expected to show stable growth in the future market. However, product di......
  • Global Autism Spectrum Disorder Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 110
    Report Overview: Autism spectrum disorder is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests and activities. Diagnosing autism spectrum disorder (ASD) can be difficult, since there is no medical test, like a blood test, to diagnose the disorders. Doctors look at the child's behavior and development to make a diagnosis. Our report studies the market......
  • Global Epilepsy Therapeutics Market Research Report 2023
    Published: 14-Dec-2023        Price: US 2900 Onwards        Pages: 86
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Epilepsy Therapeutics market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Laboratories - Cephalon - Novartis - Pfizer - Johnson & Johnson - GlaxoSmithKline - Sanofi - Sunovion Pharmaceuticals......
  • Global Autism Spectrum Disorder Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 109
    Market Overview of Global Autism Spectrum Disorder market: According to our latest research, the global Autism Spectrum Disorder market looks promising in the next 5 years. As of 2022, the global Autism Spectrum Disorder market was estimated at USD 464.19 million, and it's anticipated to reach USD 700.88 million in 2028, with a CAGR of 7.11% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of ......
  • Global Autism Spectrum Disorder Market Status and Outlook 2023-2028
    Published: 24-Nov-2023        Price: US 3160 Onwards        Pages: 109
    Autism spectrum disorder (ASD) is a complex developmental condition that involves persistent challenges in social interaction, speech and nonverbal communication, and restricted/repetitive behaviors. The effects of ASD and the severity of symptoms are different in each person. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segmen......
  • Global Epilepsy Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Epilepsy Therapeutics market: According to our latest research, the global Epilepsy Therapeutics market looks promising in the next 5 years. As of 2022, the global Epilepsy Therapeutics market was estimated at USD 11157.84 million, and it's anticipated to reach USD 13510.46 million in 2028, with a CAGR of 3.24% during the forecast years. Epilepsy is a group of neurological disorders characterized by seizures. The onset of a seizure can range from a b......
  • Global Gabapentin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Oct-2023        Price: US 3380 Onwards        Pages: 98
    Market Overview of Global Gabapentin market: According to our latest research, the global Gabapentin market looks promising in the next 5 years. As of 2022, the global Gabapentin market was estimated at USD 1627.13 million, and it's anticipated to reach USD 1844.92 million in 2028, with a CAGR of 2.12% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Gabapentin market, with a sys......
  • 2023-2031 Report on Global Autism Spectrum Disorder Market by Player, Region, Type, Application and Sales Channel
    Published: 09-Oct-2023        Price: US 2500 Onwards        Pages: 89
    This report studies the Autism Spectrum Disorder market, covering market size for segment by type (Center-Based, In-Home, etc.), by application (1-14 Years Old, 15-25 Years Old, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Otsuka, Astrazeneca, Pfizer, Eli Lilly, Johnson & Johnson, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Aut......
  • Global Gabapentin Market Insights, Forecast to 2029
    Published: 27-Sep-2023        Price: US 4900 Onwards        Pages: 112
    Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain. The global Gabapentin market is projected to grow from US$ 1572.1 million in 2023 to US$ 1749.7 million by 2029, at a Compound Annual Growth Ra......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs